1. Home
  2. EFOI vs CINGW Comparison

EFOI vs CINGW Comparison

Compare EFOI & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFOI
  • CINGW
  • Stock Information
  • Founded
  • EFOI 1985
  • CINGW N/A
  • Country
  • EFOI United States
  • CINGW United States
  • Employees
  • EFOI N/A
  • CINGW 13
  • Industry
  • EFOI Building Products
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFOI Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • EFOI Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • EFOI N/A
  • CINGW N/A
  • IPO Year
  • EFOI 1994
  • CINGW 2021
  • Fundamental
  • Price
  • EFOI $1.72
  • CINGW $0.05
  • Analyst Decision
  • EFOI
  • CINGW
  • Analyst Count
  • EFOI 0
  • CINGW 0
  • Target Price
  • EFOI N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • EFOI 17.4K
  • CINGW N/A
  • Earning Date
  • EFOI 05-12-2025
  • CINGW N/A
  • Dividend Yield
  • EFOI N/A
  • CINGW N/A
  • EPS Growth
  • EFOI N/A
  • CINGW N/A
  • EPS
  • EFOI N/A
  • CINGW N/A
  • Revenue
  • EFOI $4,860,000.00
  • CINGW N/A
  • Revenue This Year
  • EFOI N/A
  • CINGW N/A
  • Revenue Next Year
  • EFOI N/A
  • CINGW N/A
  • P/E Ratio
  • EFOI N/A
  • CINGW N/A
  • Revenue Growth
  • EFOI N/A
  • CINGW N/A
  • 52 Week Low
  • EFOI $1.14
  • CINGW N/A
  • 52 Week High
  • EFOI $2.95
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • EFOI 37.94
  • CINGW N/A
  • Support Level
  • EFOI $1.74
  • CINGW N/A
  • Resistance Level
  • EFOI $1.86
  • CINGW N/A
  • Average True Range (ATR)
  • EFOI 0.12
  • CINGW 0.00
  • MACD
  • EFOI -0.06
  • CINGW 0.00
  • Stochastic Oscillator
  • EFOI 1.92
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: